HRP20181572T1 - Režim doziranja spoja fgf-18 - Google Patents

Režim doziranja spoja fgf-18

Info

Publication number
HRP20181572T1
HRP20181572T1 HRP20181572TT HRP20181572T HRP20181572T1 HR P20181572 T1 HRP20181572 T1 HR P20181572T1 HR P20181572T T HRP20181572T T HR P20181572TT HR P20181572 T HRP20181572 T HR P20181572T HR P20181572 T1 HRP20181572 T1 HR P20181572T1
Authority
HR
Croatia
Prior art keywords
fgf
compound
dosage mode
dosage
mode
Prior art date
Application number
HRP20181572TT
Other languages
English (en)
Croatian (hr)
Inventor
Christoph H. Ladel
Hans Guehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20181572T1 publication Critical patent/HRP20181572T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181572TT 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18 HRP20181572T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
EP15707076.4A EP3119417B1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (1)

Publication Number Publication Date
HRP20181572T1 true HRP20181572T1 (hr) 2018-11-30

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20181572TT HRP20181572T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18
HRP20181570TT HRP20181570T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181570TT HRP20181570T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18

Country Status (25)

Country Link
US (2) US9889179B2 (enExample)
EP (2) EP3107559B1 (enExample)
JP (2) JP6431082B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106232622A (enExample)
AR (2) AR099510A1 (enExample)
AU (2) AU2015220777B2 (enExample)
BR (2) BR112016018696A2 (enExample)
CA (1) CA2938791A1 (enExample)
DK (2) DK3119417T3 (enExample)
ES (2) ES2688551T3 (enExample)
HR (2) HRP20181572T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247083B (enExample)
LT (2) LT3107559T (enExample)
MX (2) MX2016010872A (enExample)
NZ (1) NZ723148A (enExample)
PL (2) PL3119417T3 (enExample)
PT (2) PT3107559T (enExample)
RS (2) RS57853B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606502YA (enExample)
SI (2) SI3119417T1 (enExample)
WO (2) WO2015124727A1 (enExample)
ZA (2) ZA201605547B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
BR112016018681B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura
WO2016120387A1 (en) 2015-01-29 2016-08-04 Ares Trading S.A. Immunoassays for high positively charged proteins
DK3419625T3 (da) 2016-02-22 2021-07-12 Novartis Ag Fremgangsmåder til anvendelse af fxr-agonister
PL3688468T3 (pl) 2017-09-29 2022-07-18 Merck Patent Gmbh Biomarkery stanu zapalnego do przewidywania odpowiedzi na związek fgf-18
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
US20220184180A1 (en) * 2019-02-08 2022-06-16 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
KR102920449B1 (ko) 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
ES2706848T3 (es) * 2004-07-06 2019-04-01 Zymogenetics Inc Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
CA2658511C (en) 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
ZA200900426B (en) * 2006-08-25 2010-04-28 Ares Trading Sa Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
BR112016018681B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura

Also Published As

Publication number Publication date
EP3107559A1 (en) 2016-12-28
EP3107559B1 (en) 2018-07-11
JP6431082B2 (ja) 2018-11-28
BR112016018696A2 (pt) 2017-10-17
AU2015220777A1 (en) 2016-09-01
ES2688551T3 (es) 2018-11-05
MX2016010872A (es) 2016-11-17
AR099558A1 (es) 2016-08-03
KR20160116001A (ko) 2016-10-06
PL3107559T3 (pl) 2019-01-31
KR20160116000A (ko) 2016-10-06
US9889179B2 (en) 2018-02-13
PT3119417T (pt) 2018-10-31
PL3119417T3 (pl) 2019-01-31
IL247084B (en) 2019-09-26
JP2017512194A (ja) 2017-05-18
AU2015220773B2 (en) 2020-10-08
PT3107559T (pt) 2018-10-31
SI3107559T1 (sl) 2018-11-30
LT3119417T (lt) 2018-10-25
KR102410988B1 (ko) 2022-06-17
DK3119417T3 (en) 2018-10-22
US20170072017A1 (en) 2017-03-16
AU2015220773A1 (en) 2016-09-01
LT3107559T (lt) 2018-10-25
ZA201605548B (en) 2018-12-19
IL247083A0 (en) 2016-09-29
CN106456713A (zh) 2017-02-22
SG11201606505UA (en) 2016-09-29
NZ723148A (en) 2022-08-26
IL247084A0 (en) 2016-09-29
BR112016018685A2 (pt) 2017-10-17
WO2015124727A1 (en) 2015-08-27
RU2691946C2 (ru) 2019-06-19
SI3119417T1 (sl) 2018-11-30
AU2015220777B2 (en) 2020-10-22
JP2017507142A (ja) 2017-03-16
ES2689071T3 (es) 2018-11-08
RU2016137292A3 (enExample) 2018-09-17
DK3107559T3 (en) 2018-10-15
EP3119417B1 (en) 2018-07-11
IL247083B (en) 2019-09-26
NZ723139A (en) 2022-12-23
KR102410986B1 (ko) 2022-06-17
WO2015124731A1 (en) 2015-08-27
HRP20181570T1 (hr) 2018-11-30
ZA201605547B (en) 2019-09-25
US20170056474A1 (en) 2017-03-02
RU2016137289A3 (enExample) 2018-10-19
US9724388B2 (en) 2017-08-08
RS57709B1 (sr) 2018-12-31
MX2016010871A (es) 2016-11-17
AR099510A1 (es) 2016-07-27
RS57853B1 (sr) 2018-12-31
CN106232622A (zh) 2016-12-14
EP3119417A1 (en) 2017-01-25
SG11201606502YA (en) 2016-09-29
RU2016137289A (ru) 2018-03-21
HUE040350T2 (hu) 2019-03-28
RU2700582C2 (ru) 2019-09-18
RU2016137292A (ru) 2018-03-21
CA2938791A1 (en) 2015-08-27
CA2938793A1 (en) 2015-08-27
JP6431083B2 (ja) 2018-11-28

Similar Documents

Publication Publication Date Title
IL281863A (en) Pharmaceutical compositions comprising meloxicam
HUE047477T2 (hu) Palbociclib szilárd dózisformái
HUE050732T2 (hu) Új vegyületek
LT3134402T (lt) 4-amino-imidazochinolino junginiai
DK3310231T3 (da) Doseringsindretning
HUE042964T2 (hu) Szubsztituált dihidro-izokinolinon vegyületek
HUE059694T2 (hu) Készítmény rák kezelésére
HUE059158T2 (hu) Eljárás pridopidin elõállítására
PT3298027T (pt) Compostos depsipéptidos antelmínticos
HRP20181570T1 (hr) Režim doziranja spoja fgf-18
DK3145488T3 (da) Flydende farmaceutiske forbindelse
DK3363428T3 (da) Perfusionsdoseringsform
DK3283210T3 (da) Fremgangsmåde
BR112016030730A2 (pt) Composto
LT3212237T (lt) Metotreksato vaistinė forma
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
HUE054351T2 (hu) Vegyületek
IL250613B (en) Substituted bicyclic compounds
DK3597189T3 (da) Krystallinske forbindelser
IL246509A0 (en) Coordinating multiple components
IL254502A0 (en) Solid forms of menaquinols
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
HUE054584T2 (hu) Maropitant készítmény
EP3334447A4 (en) CCK2R-drug conjugates